STOCK TITAN

Windtree Therapeutics, Inc. - WINT STOCK NEWS

Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.

Windtree Therapeutics, Inc. (NASDAQ: WINT) is a pioneering biotechnology company specializing in the development of innovative therapies for critical cardiovascular and respiratory conditions. The company's advanced research and proprietary technologies aim to address significant unmet medical needs, offering hope to patients and their families.

At the core of Windtree's portfolio is its KL4 surfactant technology, a synthetic, peptide-containing surfactant structurally similar to human pulmonary surfactant. This technology is being developed for noninvasive administration via aerosolization, with a primary focus on treating Respiratory Distress Syndrome (RDS) in premature infants. The potential of this technology extends to various other respiratory diseases, promising new therapeutic avenues where few or no approved treatments exist.

In the cardiovascular domain, Windtree is advancing istaroxime, a Phase 2 candidate exhibiting unique dual mechanisms that enhance both systolic and diastolic cardiac functions. Istaroxime targets acute heart failure and cardiogenic shock, conditions with high mortality and limited treatment options. Recent collaborations, including a significant license agreement with Lee's Pharmaceutical, aim to develop and commercialize istaroxime in Greater China, reflecting its global potential.

Windtree is also exploring preclinical SERCA2a activators for heart failure, aiming to develop both intravenous and oral formulations to treat acute and chronic heart failure, respectively. Additionally, the company is advancing rostafuroxin, targeting hypertension in patients with specific genetic markers, and a preclinical atypical protein kinase C iota (aPKCi) inhibitor, for potential oncology applications.

Financially, Windtree's strategic licensing and partnerships, such as the recent agreement with Deerfield Management to retire a $15 million liability, have strengthened its balance sheet. The company is strategically positioned to advance its late-stage clinical programs while optimizing its financial resources to support ongoing and future endeavors.

Windtree's commitment to scientific innovation and strategic collaborations is poised to transform treatment paradigms in cardiovascular and respiratory care, with a robust pipeline that holds significant promise for the future.

Rhea-AI Summary

Windtree Therapeutics (WINT) announced that Dr. Alexandre Mebazaa, a leading expert in cardiogenic shock, presented data from the Phase 2b SEISMiC B study of istaroxime at the Cardiovascular Clinical Trials Conference in Washington, DC. Istaroxime, a first-in-class investigational therapy for early cardiogenic shock due to heart failure, has shown positive results in four Phase 2 trials. The drug demonstrated ability to rapidly increase blood pressure and improve cardiac output without increasing heart rate, while maintaining renal function and showing a favorable safety profile. The company plans to advance istaroxime to Phase 3 trials in cardiogenic shock treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.74%
Tags
-
Rhea-AI Summary

Windtree Therapeutics has filed a new PCT patent application for istaroxime derivatives aimed at preventing or reducing the risk of acute myocardial arrhythmia. The filing builds on data from animal model testing and human clinical trials for acute heart failure (AHF) and early cardiogenic shock (ECS), including a positive Phase 2b study in ECS patients. Istaroxime has demonstrated beneficial effects in rat studies with ischemia-reperfusion induced arrhythmias, showing potential as a therapeutic for improving cardiac function in patients with ischemia. The drug has shown no increase in clinically significant cardiac arrhythmias in Phase 2 trials, potentially due to its SERCA2a activation, differentiating it from current treatments. The company believes these unique aspects justify intellectual property protection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
Rhea-AI Summary

Windtree Therapeutics (NASDAQ: WINT) has partnered with New Growth Advisors (NGA) to explore strategic opportunities for its cardiovascular portfolio, including potential out-licensing or asset sale. The company aims to capitalize on positive Phase 2 results for istaroxime in cardiogenic shock and acute heart failure.

NGA, which has advised on transactions worth nearly $400 million in 2023-2024, will manage current interest and lead an expanded out-licensing process. Windtree already has a licensing agreement with Lee's Pharmaceuticals for Greater China territory, potentially worth up to $138 million in milestones plus royalties. Lee's plans to initiate Phase 3 trials in acute heart failure in their licensed territory in first half 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.39%
Tags
partnership clinical trial
Rhea-AI Summary

Windtree Therapeutics (WINT) reported Q3 2024 financial results and key updates. The company announced positive Phase 2b results for istaroxime in early cardiogenic shock, showing significant improvements in cardiac function and blood pressure. The company completed two private placements for $13.9 million and secured a $35 million equity line agreement. Q3 operating loss was $4.7 million with cash and equivalents of $2.3 million as of September 30, 2024. The company expects current funding to support operations through January 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13%
Tags
-
Rhea-AI Summary

Windtree Therapeutics (NASDAQ: WINT) announced a leadership transition as CEO Craig Fraser plans to retire effective December 1, 2024, after nearly nine years of service. Fraser will remain as Board Chairman while Jed Latkin, a current director, will assume the CEO position. During Fraser's tenure since 2016, the company achieved several milestones including clinical studies, Nasdaq uplisting, and various transactions. Latkin brings nearly three decades of financial and biotech experience, including previous CEO roles at Navidea Biopharmaceuticals and Black Elk Energy Offshore, with extensive experience in dealmaking and fund raising.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
management
-
Rhea-AI Summary

Windtree Therapeutics (WINT) has announced the issuance of an istaroxime patent in Hong Kong, valid until 2039. The patent covers formulations and methods of use for istaroxime in acute heart failure (AHF) treatment. This development supports the company's licensing agreement with Lee's Pharmaceutical, which is planning Phase 3 trials in Greater China. Lee's will fund all regional development, with Windtree maintaining protocol authority. The agreement could yield up to $138 million in milestones plus double-digit royalties for Windtree. Istaroxime, studied in four positive Phase 2 trials, is designed to improve heart function while maintaining renal function.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none
Rhea-AI Summary

Windtree Therapeutics (WINT) has initiated enrollment in the SEISMiC C trial for SCAI Stage C cardiogenic shock, following positive results from SEISMiC A and B trials. The study evaluates istaroxime in more severely ill patients who require inotropic or vasopressor drugs. The global, placebo-controlled trial will assess istaroxime's effectiveness when added to standard care, with primary focus on systolic blood pressure profile over 6 hours. A data review is planned for late Q1/early Q2 2025. Previous trials showed istaroxime improved blood pressure, cardiac and renal function without increased arrhythmia risks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.5%
Tags
-
Rhea-AI Summary

Windtree Therapeutics (NASDAQ: WINT) has completed national phase patent filings for its istaroxime formulation across major global markets, including the United States, Germany, France, Italy, Japan, and China. The patent, numbered PCT/US2023/018998 and application No. 18/858,086, is titled 'ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF PRE-CARDIOGEN1C SHOCK AND CARDIOGENIC SHOCK'. This strategic move aims to strengthen the company's intellectual property position for istaroxime in treating cardiogenic shock patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
-
Rhea-AI Summary

Windtree Therapeutics (NasdaqCM: WINT), a biotechnology company focusing on innovative therapies for critical conditions, has announced its participation in the ThinkEquity Conference on October 30th. Craig Fraser, Chairman and CEO, will present a corporate update at 12:30pm ET and participate in one-on-one meetings with investors.

The presentation will cover:

  • Recent positive topline data results from the Phase 2b SEISMiC Extension Study
  • Updates on the company's lead drug candidate, istaroxime, for heart failure associated early cardiogenic shock
  • Company strategy and planned milestones

This event provides an opportunity for Windtree to showcase its progress in developing therapies for critical conditions and diseases to potential investors and industry professionals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.16%
Tags
conferences
Rhea-AI Summary

Windtree Therapeutics (NasdaqCM: WINT) has announced the issuance of a new patent for istaroxime in Japan. The patent, titled 'Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF),' covers intravenous administration of istaroxime with increased infusion times, alone or combined with other AHF treatments. This method aims to improve heart failure treatment and diastolic relaxation compared to conventional protocols.

The patent (No. 7560134) was registered on September 24, 2024, and will expire in 2039. Istaroxime, Windtree's novel first-in-class investigational therapy, has shown positive results in four Phase 2 trials for acute heart failure and early cardiogenic shock. The company views this patent issuance as an important step in expanding and strengthening its cardiovascular platform patent estate in key markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.49%
Tags
none

FAQ

What is the current stock price of Windtree Therapeutics (WINT)?

The current stock price of Windtree Therapeutics (WINT) is $0.325 as of December 23, 2024.

What is the market cap of Windtree Therapeutics (WINT)?

The market cap of Windtree Therapeutics (WINT) is approximately 2.9M.

What is Windtree Therapeutics' primary focus?

Windtree Therapeutics focuses on developing innovative therapies for critical cardiovascular and respiratory conditions.

What is the KL4 surfactant technology?

KL4 surfactant technology is a synthetic, peptide-containing surfactant structurally similar to human pulmonary surfactant, aimed at treating respiratory diseases, including RDS in premature infants.

What is istaroxime?

Istaroxime is a Phase 2 candidate developed by Windtree Therapeutics to treat acute heart failure and cardiogenic shock by improving both systolic and diastolic cardiac functions.

What recent partnership has Windtree Therapeutics engaged in?

Windtree Therapeutics has entered a significant partnership with Lee's Pharmaceutical to develop and commercialize istaroxime in Greater China.

What is rostafuroxin?

Rostafuroxin is a drug candidate targeting hypertension in patients with specific genetic profiles, currently under development by Windtree Therapeutics.

How has Windtree Therapeutics strengthened its financial position?

Windtree has strengthened its financial position through strategic licensing agreements and partnerships, such as retiring a $15 million liability with Deerfield Management.

What are SERCA2a activators?

SERCA2a activators are compounds developed by Windtree that enhance cardiac function and are being explored for both intravenous and oral treatments for heart failure.

What is the potential market impact of istaroxime?

If approved, istaroxime could become a standard treatment for improving blood pressure and heart function in patients with acute heart failure and cardiogenic shock.

What is Windtree's approach to oncology?

Windtree is developing a preclinical atypical protein kinase C iota (aPKCi) inhibitor for potential applications in rare and broad oncology indications.

Where can I find more detailed financial information about Windtree Therapeutics?

Detailed financial information can be found in Windtree's Annual Report on Form 10-K and other filings available at www.sec.gov.

Windtree Therapeutics, Inc.

Nasdaq:WINT

WINT Rankings

WINT Stock Data

2.89M
8.96M
0.27%
2.06%
0.35%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WARRINGTON